Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Executive Summary

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Advertisement

Related Content

Sun Acquires Novartis Cancer Drug In Specialty Push
Sunovion To Commercialize Novartis’s COPD Products In US
Was Sanofi’s Offer One That Actelion Could Refuse? J&J Back At Bargaining Table
Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs
Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Novartis Hopes Encore Can Lead To Eye-Watering Presbyopia Success
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
BioInvent Stumbles In Busy Multiple Myeloma Space
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel